Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
March 4, 2011
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10
Hongwei Wang, Fengdong Cheng, Karrune Woan, et al.
Nature Immunology
|
January 29, 2013
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
Je-In Youn, Vinit Kumar, Michelle Collazo, et al.
Nature Immunology
|
November 18, 2008
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.
Molecular Immunology
|
April 22, 2014
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells
Fengdong Cheng, Maritza Lienlaf, Patricio Perez-Villarroel, et al.
Scientific Reports
|
February 28, 2020
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
Sara Moufarrij, Aneil Srivastava, Stephanie Gomez, et al.
Cancer Research
|
July 2, 2020
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer
Debarati Banik, Satish Noonepalle, Melissa Hadley, et al.
Molecular and Cellular Biology
|
April 17, 2003
Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity
Jose Sierra, Alejandro Villagra, Roberto Paredes, et al.
Bone Marrow Transplantation
|
April 20, 2018
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease
Lia Perez, Hugo Fernandez, Pedro Horna, et al.
Scientific Reports
|
October 11, 2019
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports
|
April 18, 2019
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Journal of Immunology (Baltimore, Md. : 1950)
|
March 4, 2011
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10
Hongwei Wang, Fengdong Cheng, Karrune Woan, et al.
Nature Immunology
|
January 29, 2013
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
Je-In Youn, Vinit Kumar, Michelle Collazo, et al.
Nature Immunology
|
November 18, 2008
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.
Molecular Immunology
|
April 22, 2014
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells
Fengdong Cheng, Maritza Lienlaf, Patricio Perez-Villarroel, et al.
Scientific Reports
|
February 28, 2020
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
Sara Moufarrij, Aneil Srivastava, Stephanie Gomez, et al.
Cancer Research
|
July 2, 2020
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer
Debarati Banik, Satish Noonepalle, Melissa Hadley, et al.
Molecular and Cellular Biology
|
April 17, 2003
Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity
Jose Sierra, Alejandro Villagra, Roberto Paredes, et al.
Bone Marrow Transplantation
|
April 20, 2018
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease
Lia Perez, Hugo Fernandez, Pedro Horna, et al.
Scientific Reports
|
October 11, 2019
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports
|
April 18, 2019
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Page
of 6